Qualit-E-SpeakPharma-Insert
X

Find Drugs for Infections and Infectious Diseases in Phase I Clinical Development in CHINA

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Ad5-nCoV

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Phase I Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 17, 2020

            Details:

            Joint developers submitted pre-investigational new drug review application for AD5-NCOV to regulatory authorities.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): TJM2

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 13, 2020

            Details:

            The development will start following the FDA acceptance of I-Mab’s Investigational New Drug application, and the study will commence initially in the U.S. with plans to expand into other countries.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ZM-H1505R

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 05, 2020

            Details:

            Primary results showed that the drug is safe and well tolerated in health volunteers tested.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ASC22

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Phase I Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 22, 2020

            Details:

            ASC22 is a first-in-class, subcutaneously administered PD-L1 antibody approved for such clinical trials in HBV patients on a global basis.